Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 14592977 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Cheung PC, Campbell DG, Nebreda AR, Cohen P (2003) Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 22, 5793-805 14592977
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S423-p - TAB1 (human) ▲
Orthologous residues
TAB1 (human): S423‑p, TAB1 (mouse): S421‑p, TAB1 (rat): S421‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  cervical cancer, cervical squamous cell carcinoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), KB (squamous), RAW 264 (macrophage)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
SB203580 LPS inhibit treatment-induced increase
PD184352 LPS no effect upon treatment-induced increase
TNF increase
SB203580 TNF inhibit treatment-induced increase
PD184352 TNF no effect upon treatment-induced increase
IL-1a increase
SB203580 IL-1a inhibit treatment-induced increase
PD184352 IL-1a no effect upon treatment-induced increase
H2O2 increase
SB203580 H2O2 inhibit treatment-induced increase
PD184352 H2O2 no effect upon treatment-induced increase
UV increase
SB203580 UV inhibit treatment-induced increase
PD184352 UV no effect upon treatment-induced increase
anisomycin increase
SB203580 anisomycin inhibit treatment-induced increase
PD184352 anisomycin no effect upon treatment-induced increase
sorbitol increase
SB203580 sorbitol inhibit treatment-induced increase
PD184352 sorbitol no effect upon treatment-induced increase

T431-p - TAB1 (human) ▲
Orthologous residues
TAB1 (human): T431‑p, TAB1 (mouse): T429‑p, TAB1 (rat): T429‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  cervical cancer, cervical squamous cell carcinoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), KB (squamous), RAW 264 (macrophage)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
SB203580 LPS inhibit treatment-induced increase
PD184352 LPS no effect upon treatment-induced increase
TNF increase
SB203580 TNF inhibit treatment-induced increase
PD184352 TNF no effect upon treatment-induced increase
IL-1a increase
SB203580 IL-1a inhibit treatment-induced increase
PD184352 IL-1a no effect upon treatment-induced increase
H2O2 increase
SB203580 H2O2 inhibit treatment-induced increase
PD184352 H2O2 no effect upon treatment-induced increase
UV increase
SB203580 UV inhibit treatment-induced increase
PD184352 UV no effect upon treatment-induced increase
anisomycin increase
SB203580 anisomycin inhibit treatment-induced increase
PD184352 anisomycin no effect upon treatment-induced increase
sorbitol increase
SB203580 sorbitol inhibit treatment-induced increase
PD184352 sorbitol no effect upon treatment-induced increase

S438-p - TAB1 (human) ▲
Orthologous residues
TAB1 (human): S438‑p, TAB1 (mouse): S436‑p, TAB1 (rat): S436‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  cervical cancer, cervical squamous cell carcinoma
 Relevant cell lines - cell types - tissues:  293 (epithelial), KB (squamous), RAW 264 (macrophage)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
SB203580 LPS no effect upon treatment-induced increase
PD184352 LPS inhibit treatment-induced increase
TNF no change compared to control
SB203580 TNF no change compared to control
PD184352 TNF no change compared to control
IL-1a increase
SB203580 IL-1a no effect upon treatment-induced increase
PD184352 IL-1a inhibit treatment-induced increase
H2O2 increase
SB203580 H2O2 no effect upon treatment-induced increase
PD184352 H2O2 inhibit treatment-induced increase
UV increase
SB203580 UV no effect upon treatment-induced increase
PD184352 UV inhibit treatment-induced increase
anisomycin increase
SB203580 anisomycin no effect upon treatment-induced increase
PD184352 anisomycin no effect upon treatment-induced increase
sorbitol increase
SB203580 sorbitol no effect upon treatment-induced increase
PD184352 sorbitol inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.